HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that it has provided notice to the patent and New Drug Application (NDA) holders that it has submitted an Abbreviated New Drug Application (ANDA) for doxycyline hyclate delayed-release tablets 150 mg, generic of Doryx®, to the U.S. Food and Drug Administration (FDA). Impax’s ANDA, contains a Paragraph IV certification stating that the Company believes its product does not infringe US Patent No. 6,958,161, or that the patent is invalid or unenforceable.
